Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker R H
Yehuda Abarbanel Mental Health Center, Bat Yam, Israel.
Am J Psychiatry. 1995 May;152(5):792-4. doi: 10.1176/ajp.152.5.792.
CSF levels of inositol have been reported to be lower than normal in depressed subjects. The authors administered inositol to depressed patients in a double-blind, controlled trial.
Under double-blind conditions, 12 g/day of inositol (N = 13) or placebo (N = 15) was administered to depressed patients for 4 weeks.
The overall improvement in scores on the Hamilton Depression Rating Scale was significantly greater for inositol than for placebo at week 4. No changes were noted in hematology or in kidney or liver function.
This may be the first use of the precursor strategy for a second messenger rather than a neurotransmitter in treating depression. Although inositol had a significant antidepressant effect in this study, replication is crucial.
据报道，抑郁症患者脑脊液中肌醇水平低于正常水平。作者在一项双盲对照试验中给抑郁症患者服用肌醇。
在双盲条件下，给抑郁症患者每日服用12克肌醇（n = 13）或安慰剂（n = 15），持续4周。
在第4周时，肌醇组汉密尔顿抑郁量表评分的总体改善程度显著大于安慰剂组。血液学指标以及肾功能和肝功能均未发现变化。
这可能是首次将第二信使而非神经递质的前体策略用于治疗抑郁症。尽管在本研究中肌醇具有显著的抗抑郁作用，但重复验证至关重要。
